Resistance to epidermal growth factor receptor-targeted therapy-Reference-Cited by-同舟云学术

Resistance to epidermal growth factor receptor-targeted therapy

Published:2005-10 Issue:5 Volume:8 Page:298-310
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Morgillo Floriana,Lee Ho-Young

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference128 articles.

1. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase;Ahmad;J. Biol. Chem.,2004

2. The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery;Alaoui-Jamali;Drug Resist. Update,2003

3. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors;Amador;Cancer Res.,2004

4. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer;Amann;Cancer Res.,2005

5. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia;Arteaga;J. Clin. Oncol.,2001

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy;WIREs Nanomedicine and Nanobiotechnology;2024-09

2. Construction of a bacteriophage-derived vector with potential applications in targeted drug delivery and cell imaging;Biotechnology Letters;2024-01-06

3. Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy;Biomedicine & Pharmacotherapy;2023-09

4. Design and synthesis of peptide-drug conjugates to double target EGFR;Phytochemistry Letters;2023-08

5. Emerging advances in engineered macrophages for tumor immunotherapy;Cytotherapy;2023-03